Literature DB >> 17915568

Glycogen storage disease type II: clinical overview.

M Di Rocco1, D Buzzi, M Tarò.   

Abstract

Glycogen storage disease type II has a broad continuous clinical spectrum in terms of onset, involvement of organs and life expectancy. Infantile onset is the most severe form, presenting with prominent cardiomyopathy, hypotonia, hepatomegaly and death before 12 months of life. Late onset form has onset at any age, lack of severe (or absence of) cardiac involvement, progressive skeletal muscle dysfunction and less dismal short-term prognosis. In addition to muscle and heart involvement, other tissues are affected liver, spleen, endothelium, lung, brain, anterior horns, peripheral nerves. In fact some patients with infantile form have hearing loss, abnormal brain myelination and central fever and some adult patients show aneurysms of brain arteries due to accumulation of glycogen in vessels. As for other treatable lysosomal diseases, the advent of enzyme replacement therapy will change the natural history of this disease and also will increase our knowledge concerning clinical heterogeneity.

Entities:  

Mesh:

Year:  2007        PMID: 17915568      PMCID: PMC2949314     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  14 in total

1.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

Authors:  Priya S Kishnani; Wuh-Liang Hwu; Hanna Mandel; Marc Nicolino; Florence Yong; Deyanira Corzo
Journal:  J Pediatr       Date:  2006-05       Impact factor: 4.406

2.  Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease.

Authors:  F Martiniuk; A Chen; A Mack; E Arvanitopoulos; Y Chen; W N Rom; W J Codd; B Hanna; P Alcabes; N Raben; P Plotz
Journal:  Am J Med Genet       Date:  1998-08-27

Review 3.  The natural course of non-classic Pompe's disease; a review of 225 published cases.

Authors:  Léon P F Winkel; Marloes L C Hagemans; Pieter A van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2005-08       Impact factor: 4.849

4.  Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Shinn-Forng Peng; Wuh-Liang Hwu
Journal:  Pediatr Res       Date:  2006-07-20       Impact factor: 3.756

5.  Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.

Authors:  M G Ausems; J Verbiest; M P Hermans; M A Kroos; F A Beemer; J H Wokke; L A Sandkuijl; A J Reuser; A T van der Ploeg
Journal:  Eur J Hum Genet       Date:  1999-09       Impact factor: 4.246

Review 6.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

Authors:  Nina Raben; Paul Plotz; Barry J Byrne
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

7.  Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency.

Authors:  M G Ausems; K ten Berg; M A Kroos; O P van Diggelen; R A Wevers; B J Poorthuis; K E Niezen-Koning; A T van der Ploeg; F A Beemer; A J Reuser; L A Sandkuijl; J H Wokke
Journal:  Community Genet       Date:  1999

8.  Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.

Authors:  Johanna M P Van den Hout; Joep H J Kamphoven; Léon P F Winkel; Willem F M Arts; Johannes B C De Klerk; M Christa B Loonen; Arnold G Vulto; Adri Cromme-Dijkhuis; Nynke Weisglas-Kuperus; Wim Hop; Hans Van Hirtum; Otto P Van Diggelen; Marijke Boer; Marian A Kroos; Pieter A Van Doorn; Edwin Van der Voort; Barbara Sibbles; Emiel J J M Van Corven; Just P J Brakenhoff; Johan Van Hove; Jan A M Smeitink; Gerard de Jong; Arnold J J Reuser; Ans T Van der Ploeg
Journal:  Pediatrics       Date:  2004-05       Impact factor: 7.124

9.  Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease.

Authors:  Haoyue Zhang; Helmut Kallwass; Sarah P Young; Cortney Carr; Jian Dai; Priya S Kishnani; David S Millington; Joan Keutzer; Yuan-Tsong Chen; Deeksha Bali
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

10.  Pompe disease diagnosis and management guideline.

Authors:  Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

View more
  10 in total

1.  Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism.

Authors:  George Chinedu Ezeji; Taiga Inoue; Gul Bahtiyar; Alan Sacerdote
Journal:  BMJ Case Rep       Date:  2015-02-09

Review 2.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

3.  Recent developments, utilization, and spending trends for pompe disease therapies.

Authors:  Jing Guo; Christina M L Kelton; Jeff J Guo
Journal:  Am Health Drug Benefits       Date:  2012-05

4.  The brain in late-onset glycogenosis II: a structural and functional MRI study.

Authors:  Barbara Borroni; M S Cotelli; E Premi; S Gazzina; M Cosseddu; A Formenti; R Gasparotti; M Filosto; A Padovani
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

5.  GAA gene mutation detection following clinical evaluation and enzyme activity analysis in Azeri Turkish patients with Pompe disease.

Authors:  Jalal Gharesouran; Abbas Jalaiei; Aida Hosseinzadeh; Soudeh Ghafouri-Fard; Zeinab Mokhtari; Kazem Ghahremanzadeh; Narges Rezazadeh; Shadi Shiva; Shahram Sadeghvand; Mohammad Taheri; Maryam Rezazadeh
Journal:  Metab Brain Dis       Date:  2020-06-05       Impact factor: 3.584

6.  Genetic counseling in Pompe disease.

Authors:  Antonella Taglia; Esther Picillo; Paola D'Ambrosio; Maria Rosaria Cecio; Emanuela Viggiano; Luisa Politano
Journal:  Acta Myol       Date:  2011-12

Review 7.  NF-κB-Mediated Inflammation in the Pathogenesis of Intracranial Aneurysm and Subarachnoid Hemorrhage. Does Autophagy Play a Role?

Authors:  Elzbieta Pawlowska; Joanna Szczepanska; Karol Wisniewski; Paulina Tokarz; Dariusz J Jaskólski; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2018-04-19       Impact factor: 5.923

8.  Efficacy of Quantitative Muscle Ultrasound Using Texture-Feature Parametric Imaging in Detecting Pompe Disease in Children.

Authors:  Hong-Jen Chiou; Chih-Kuang Yeh; Hsuen-En Hwang; Yin-Yin Liao
Journal:  Entropy (Basel)       Date:  2019-07-22       Impact factor: 2.524

9.  Late-onset Pompe disease with a novel mutation and a rare phenotype: A case report.

Authors:  Xiaoli Si; Ruoxia Zhang; Shengqiang Yan; Guohua Zhao; Xinzhen Yin; Baorong Zhang
Journal:  CNS Neurosci Ther       Date:  2022-07-07       Impact factor: 7.035

10.  Late-onset Pompe disease with complicated intracranial aneurysm: a Chinese case report.

Authors:  Bin Zhang; Yuying Zhao; Junling Liu; Ling Li; Jingli Shan; Dandan Zhao; Chuanzhu Yan
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-29       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.